Monitor upcoming CORDStrom regulatory filing catalysts (MAA mid-summer, BLA Q4) and any additional XPro trial data; cash runway supports operations through key milestones without near-term dilution risk.
Price Chart
Executive Summary
INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed consensus of -$0.18 by 11%. Pipeline progress includes upcoming regulatory submissions for CORDStrom and FDA alignment for XPro, offsetting the miss.
Key Financial Metrics
Key Facts
- Q1 2026 net loss attributable to common stockholders $5.4M vs $9.7M in Q1 2025
- EPS -$0.20 missed consensus of -$0.18 (11.1% miss)
- Revenue $0; R&D expenses decreased to $3.6M from $7.6M YoY
- Cash and cash equivalents $21.4M as of March 31, 2026
- CORDStrom MAA submission to UK MHRA expected mid-summer, FDA BLA in Q4 2026
- XPro Phase 2b/3 registrational pathway aligned with FDA
Financial Impact
EPS miss of $0.02 vs consensus, no revenue impact; cash burn reduced to $3.4M operating cash flow
Risk Factors
- Clinical trial failure or regulatory delays
- No revenue; reliant on financing for operations
- Potential dilution from future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $1.61 | awaiting T+60 | — | $1.43 (−11.18%) |
Sep 16, 2026 5w ago | 3 | $2.18 | awaiting T+60 | — | $1.43 (−34.40%) |
Jul 9, 2026 15w ago | Press Release | $1.79 $1.93 | ▲ +7.82% | ▲ +6.19% | $1.43 (−20.11%) |
Jul 1, 2026 16w ago | 8-K | $1.68 | awaiting T+60 | — | $1.43 (+14.88%) |
Jun 23, 2026 17w ago | 8-K | $1.35 | awaiting T+60 | — | $1.43 (+5.93%) |
Jun 17, 2026 18w ago | 8-K | $1.45 | awaiting T+60 | — | $1.43 (−1.38%) |
Jun 2, 2026 20w ago | 8-K | $1.32 $2.40 | ▲ +81.82% | ▲ +79.32% | $1.43 (+8.33%) |
May 7, 2026 24w ago | Press Release | $1.43 $1.91 | ▲ +33.57% | ▲ +28.73% | $1.43 (−0.00%) |
May 5, 2026 24w ago | 8-K | $1.52 $1.75 | ▲ +15.13% | ▲ +13.07% | $1.43 (−5.92%) |
Apr 30, 2026 25w ago | Press Release | $1.43 | awaiting T+60 | — | $1.43 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers